News & Events

Join Us at Upcoming Events

April 2017
Sunday Monday Tuesday Wednesday Thursday Friday Saturday
March 26, 2017 March 27, 2017 March 28, 2017 March 29, 2017 March 30, 2017 March 31, 2017 April 1, 2017
April 2, 2017 April 3, 2017 April 4, 2017 April 5, 2017 April 6, 2017 April 7, 2017 April 8, 2017
April 9, 2017 April 10, 2017 April 11, 2017 April 12, 2017 April 13, 2017 April 14, 2017 April 15, 2017
April 16, 2017 April 17, 2017 April 18, 2017 April 19, 2017 April 20, 2017 April 21, 2017 April 22, 2017
April 23, 2017 April 24, 2017 April 25, 2017 April 26, 2017 April 27, 2017 April 28, 2017 April 29, 2017
April 30, 2017 May 1, 2017 May 2, 2017 May 3, 2017 May 4, 2017 May 5, 2017 May 6, 2017

25-28 April 2017
Charing Cross Symposium
London, United Kingdom

29 Jun – 1 Jul 2017
European Venous Forum
Porto, Portugal

16-20 Sep 2017
CIRSE 2017
Copenhagen, Denmark

19-22 Sep 2017
ESVS 31st Annual Meeting
Lyon, France

26-28 Oct 2017
EVF How 2017
Krakow, Poland

14-17 Nov 2017
VEITH Symposium
New York, NY

08 Sept 2016VENITI® Closes on $25M from Boston Scientific

VENITI, Inc., a leader in the advancement of treatment for deep venous disease, has closed on $25 million in Series D equity financing from Boston

20 June 2016VENITI® Announces 1,000TH Patient Treated With VICI VENOUS STENT®

Venous stent designed specifically for the challenges of the venous system achieves adoption milestone

13-14 May 2016 – VENITI®’s will present on Venous Stents at the ESVS Spring Meeting in London, UK


– Venous Stents – Design Optimization for the Clinical Challenge- Vice President of Research and Development, Stephen Kao


26-29 April 2016 – VENITI® will present the VIRTUS Trial Update at Charing Cross in London, UK


– VIRTUS Trial Update – Lowell S. Kabnick, MD, RPhS, NYU Langone MC, New York, NY

22 April 2016 – VENITI® Completes First Use Of VICI VERTO VENOUS STENT™, Novel Venous Stent System

First and only peripheral deploy venous stent system for accuracy in landing peripheral stents in patients suffering from Post Thrombotic Syndrome associated with venous outflow obstruction

17-21 November 2015 VENITI® will attend the 2015 VEITH symposium in New York, NY

3:46pm – 3:51 pm Tuesday, 17 November 2015 – Early Experience With The VENITI VICI VENOUS STENT And Update On The VIRTUS Trial, William Marston, MD, University of NC, Chapel Hill, NC

10:05am – 10:10am Thursday, 19 November 2015 – VIRTUS: An Evaluation of the VICI VENOUS STENT System In Patients with Chronic Iliofemoral Venous Outflow Obstruction, Mikel Sadek, MD, NYU Langone MC, New York, NY

10:29am – 10:34am Thursday, 19 November 2015  Luncheon Symposium – Comprehensive Review of Venous Outflow Obstruction: Diagnosis, Care Pathway and Treatment

12pm – 1pm Friday, 20 November 2015 – What is the Ideal Venous Stent, Lowell Kabnick, MD, NYU Langone MC, New York, NY

10 March 2015 – VENITI®, Inc. Announces Closing of Equity and Debt Funding

VENITI, Inc., a St. Louis, MO-based medical device company is pleased to announce that it has closed on an equity and debt financing totaling over $17 million.

9 February 2015 – Frost & Sullivan Applauds VENITI’s Dedication to Improving the Treatment of Chronic Venous Diseases (CVD) through Unique and Differentiated Products

Based on its recent analysis of the peripheral vascular devices market, Frost & Sullivan recognizes VENITI Inc. with the 2015 European Frost & Sullivan Award for new Product Innovation.

11 January 2015 – First Patients Treated in Germany with VENITI® VICI VENOUS STENT System ®

Veniti, Inc. is pleased to announce the first use of the VENITI VICI VENOUS STENT System in Germany. The System is used to treat venous outflow obstruction in the lower extremities.

5 January 2015 – The VIRTUS Trial for the VENITI® VICI Venous Stent System

Percutaneous stenting of the iliofemoral venous outflow system has evolved in to the preferred approach for management of chronic venous obstruction. The procedure can be performed with low morbidity, low mortality, long-term high patency rate, and low rate of in-stent restenosis.

1 December 2014 – VENITI®, Inc. Announces First U.S. Patients Enrolled in VIRTUS Trial

VENITI, Inc., a company dedicated to advancing the treatment of venous disease, announced that it has enrolled the first United States patients in the VIRTUS trial of the VENITI VICI™ Venous Stent System. The four procedures were performed at two sites, including the Heart and Vascular Center, St. Joseph Hospital, Orange, CA.

14 July 2014 – VENITI®, Inc. Announces FDA Approval of IDE for VENITI VICI™ Venous Stent System, First Patients Enrolled in VIRTUS Trial

VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.

10 March 2014VENITI® To Exhibit at the European Venous Forum, 26-28 June 2014.

23 January 2014 – VENITI®, Inc. Announces First Uses of Veniti Vici Venous Stent System

VENITI announced today that patients in the European Union (EU) were successfully treated for symptomatic venous outflow obstruction of the lower extremities with the Veniti Vici™ Venous Stent System. These procedures mark the first uses in patients of this novel Venous Stent from VENITI.

6 November 2013 – VENITI® Receives CE Mark Approval for Vici Venous Stent

Veniti Inc. has received approval to CE Mark the Veniti Vici™ Venous Stent, specifically designed for the treatment of adult patients who exhibit systematic venous outflow obstruction. The CE Mark allows Veniti to sell products within the European Union.


Have Questions?

We are eager to answer them. Call us directly or submit the convenient online form below.


For Public Relations, Image Permission, and Logos

Rodney Marcy
Vice President of Global Sales and Marketing
4025 Clipper Court
Fremont, CA 94538
(314) 282-3729